TransScan expands chairman Kirshner’s duties

Article

Breast imaging device developer TransScan of Ramsey, NJ, has expanded chairman Hal Kirshner’s duties to include those of president and CEO. Kirshner joined TransScan in May 1999. Before that he had served as president and CEO of Trex Medical and

Breast imaging device developer TransScan of Ramsey, NJ, has expanded chairman Hal Kirshner’s duties to include those of president and CEO. Kirshner joined TransScan in May 1999. Before that he had served as president and CEO of Trex Medical and president of Trex subsidiary Lorad (SCAN 5/12/99).

Under Kirshner’s chairmanship, TransScan received premarket approval clearance from the Food and Drug Administration for improvements in the design and operation of its TS-2000 electrical impedance breast scanning system (SCAN 11/24/99). The FDA initially cleared the unit last April for use as an adjunct to mammography for follow-up exams in patients with equivocal mammograms.

Recent Videos
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Current and Emerging Legislative Priorities for Radiology in 2025
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 1
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
Related Content
© 2025 MJH Life Sciences

All rights reserved.